Investigating the relationship between Siponimod efficacy in secondary progressive multiple sclerosis and pathogenic Th cell populations

被引：0
|
作者：
Raveney, B. [1 ,2 ]
Katsumoto, A. [2 ,3 ]
Kurosawa, R. [3 ]
Lin, Y. [2 ,3 ]
Takahashi, Y. [3 ]
Okamoto, T. [2 ,3 ]
Oki, S. [1 ]
Sato, W. [1 ,2 ]
Yamamura, T. [1 ,2 ]
机构：
[1] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Immunol, Kodaira, Tokyo, Japan
[2] Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Multiple Sclerosis Ctr, Kodaira, Tokyo, Japan
[3] Natl Ctr Neurol & Psychiat, Dept Neurol, Natl Ctr Hosp, Kodaira, Tokyo, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP0939
引用
收藏
页码：774 / 775
页数：2
相关论文
共 50 条
  • [31] Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis
    Mariottini, A.
    Filippini, S.
    Di Tullio, M. Grammatico
    Forci, B.
    Innocenti, C.
    Barilaro, A.
    Fani, A.
    Saccardi, R.
    Massacesi, L.
    Repice, A. M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 106 - 106
  • [32] Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series
    Chang, Edward H.
    Hardy, Todd A.
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2024, 389
  • [33] Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients
    Kuhle, Jens
    Kropshofer, Harald
    Barro, Christian
    Meinert, Rolf
    Haring, Dieter A.
    Leppert, David
    Tomic, Davorka
    Dahlke, Frank
    Kappos, Ludwig
    [J]. NEUROLOGY, 2018, 90
  • [34] MODELLING LONG-TERM HEALTH BENEFITS OF SIPONIMOD IN ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PORTUGAL
    Silva, C.
    Bandeiras, C.
    Laires, P. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S627 - S627
  • [35] Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
    Cortesi, Paolo Angelo
    Antonazzo, Ippazio Cosimo
    Gasperini, Claudio
    Nica, Mihaela
    Ritrovato, Daniela
    Mantovani, Lorenzo Giovanni
    [J]. PLOS ONE, 2022, 17 (03):
  • [36] The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis
    Gracien, Rene-Maxime
    Jurcoane, Alina
    Wagner, Marlies
    Reitz, Sarah C.
    Mayer, Christoph
    Volz, Steffen
    Hof, Stephanie-Michelle
    Fleischer, Vinzenz
    Droby, Amgad
    Steinmetz, Helmuth
    Zipp, Frauke
    Hattingen, Elke
    Deichmann, Ralf
    Klein, Johannes C.
    [J]. PLOS ONE, 2016, 11 (08):
  • [37] AMASIA study: Real World Insights on Siponimod Treated Patients with Secondary Progressive Multiple Sclerosis in Germany
    Hoffmann, O.
    Schreiber, H.
    Klotz, L.
    Weber, M.
    Rauser, B.
    Baufeld, C.
    Ziemssen, T.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 351 - 351
  • [38] The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
    Martin Vališ
    Anat Achiron
    Hans Peter Hartung
    Jan Mareš
    Veronika Tichá
    Pavel Štourač
    Simona Halusková
    Francesco Angelucci
    Zbyšek Pavelek
    [J]. Drugs in R&D, 2023, 23 : 331 - 338
  • [39] STICK OR TWIST? COST-EFFECTIVENESS OF SIPONIMOD IN THE TREATMENT OF ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE UK
    Montgomery, S.
    Woodhouse, F.
    Vudumula, U.
    Gudala, K.
    Kroes, M.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S55 - S56
  • [40] Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
    Abbadessa, Gianmarco
    Maida, Elisabetta
    Miele, Giuseppina
    Bile, Floriana
    Lavorgna, Luigi
    Bonavita, Simona
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
12345